BIO-key International Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

BIO-key International şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-371.8%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-371.8%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

BIO-key GAAP EPS of -$0.21, revenue of $1.9M

Aug 12

Here's Why Shareholders May Want To Be Cautious With Increasing BIO-key International, Inc.'s (NASDAQ:BKYI) CEO Pay Packet

Jun 12

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: BKYI şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: BKYI şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

BIO-key International Piyasaya Karşı Temettü Getirisi

BKYI temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (BKYI)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Software)	0.8%
Analist tahmini (BKYI) (3 yıla kadar)	n/a

Önemli Temettü: BKYI şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, BKYI şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: BKYI şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: BKYI herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

BIO-key International Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Third quarter 2024 earnings released: US$0.39 loss per share (vs US$1.26 loss in 3Q 2023)

BIO-key International, Inc. Provides Revenues Guidance for the Year 2024

BIO-key International, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Price target decreased by 40% to US$3.00

BIO-key®International, Inc.'s PortalGuard Identity and Access Management Solution and Identity-Bound Biometrics Now Available on the Amazon Web Services Marketplace

BIO-key International, Inc. to Report Q2, 2024 Results on Aug 14, 2024

BIO-key International, Inc., Annual General Meeting, Aug 22, 2024

BIO-key International, Inc. Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1)

BIO-key International, Inc. announced delayed 10-Q filing

BIO-key International, Inc. announced delayed annual 10-K filing

BIO-key International, Inc. to Report Q4, 2023 Results on Apr 02, 2024

Forecast to breakeven in 2024

BIO-key International, Inc. announced that it has received $0.547726 million in funding from Dillon Hill Capital, LLC

BIO-key International, Inc. announced delayed 10-Q filing

BIO-key International, Inc. Announces Resignation of Thomas E. Bush, III From the Board of Directors

Price target decreased by 25% to US$1.50

BIO-key International, Inc. has completed a Composite Units Offering in the amount of $3.75025 million.

BIO-key International, Inc. announced delayed 10-Q filing

Price target decreased by 60% to US$2.00

BIO-key International, Inc. to Report Q2, 2023 Results on Aug 14, 2023

BIO-Key International Receives a Letter from Nasdaq

BIO-key Regains Compliance with Nasdaq Rule Requiring Timely Filing of Periodic Financial Reports Following Filing of its First Quarter 2023 Form 10-Q with SEC

BIO-key International, Inc., Annual General Meeting, Jul 24, 2023

Bio-Key International, Inc. Appoints Cameron E. Williams to Its Board of Directors

BIO-key International Receives Notice of Non-Compliance from Nasdaq

BIO-key International, Inc. announced delayed 10-Q filing

First quarter 2023 earnings released: US$0.057 loss per share (vs US$0.13 loss in 1Q 2022)

BIO-key International, Inc. to Report Q1, 2023 Results on May 15, 2023

Insufficient new directors

BIO-key International, Inc. Announces Thomas Gilley to Resign from the Board of Directors

BIO-key Receives Nasdaq Notification Regarding $1.00 Minimum Closing Bid Price Requirement

Bio-Key International, Inc Announces Anticipation of the Planned Retirement of Fred Corsentino, Chief Revenue Officer

BIO-key International, Inc. announced that it has received $2.2 million in funding from AJB Investment Management, LLC

Price target decreased to US$4.00

Insufficient new directors

BIO-Key International, Inc. Provides Revenue Guidance for the Year 2022

BIO-key International, Inc. to Report Q3, 2022 Results on Nov 14, 2022

BIO-key International, Inc. Showcases PortalGuard Identity and Access Management Platform for Higher Education at EDUCAUSE Annual Conference October 25-28

BIO-key International, Inc. Launches Mobile Authenticator with Server-Secured and On-Device Multi-Biometric Methods to Be Showcased At 2022 Gartner IAM Summit

BIO-key International, Inc. announced delayed 10-Q filing

Insufficient new directors

BIO-key International, Inc. Provides Financial Guidance for Full-Year 2022

BIO-key GAAP EPS of -$0.21, revenue of $1.9M

BIO-key International, Inc. to Report Q2, 2022 Results on Aug 12, 2022

BIO-key Showcases Biometric Cybersecurity Solutions at MSP Expo Florida (Booth 536) to Support its Growing Distribution Base of Managed Service Providers

BIO-key International, Inc. announced delayed 10-Q filing

BIO-key International, Inc. to Report Q1, 2022 Results on May 16, 2022

BIO-key International, Inc., Annual General Meeting, Jun 24, 2022

BIO-key International, Inc. announced delayed annual 10-K filing

Bio-Key International, Inc. Provides Earnings Guidance for the Full Year 2022

Full year 2021 earnings released: US$0.65 loss per share (vs US$2.08 loss in FY 2020)

BIO-key International, Inc. (NasdaqCM:BKYI) signed a definitive agreement to acquire Swivel Secure Europe, S.A.

Bio-Key International, Inc. Launches Enhanced Admin Panel and User Experience for IT Teams Managing Its Portalguard Identity-As-A-Service (IDaaS) Solution

Insufficient new directors

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.51 loss in 3Q 2020)

BIO-key International, Inc Expands Product Line and Market Reach with Launch of FIDO2 Compliant Security Keys in a Variety of Form Factors

Forecast to breakeven in 2022

BIO-key International, Inc. Announces Improved Next-Generation EcoID II USB Compact Fingerprint Scanner

BIO-Key International, Inc. Confirms Revenue Guidance for the Full Year 2021

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.60 loss in 2Q 2020)

Bio-Key Introduces SSO Concierge™ to Its Portalguard Identity & Access Management Platform, Eliminating Passwords for Thick Client Applications

Here's Why Shareholders May Want To Be Cautious With Increasing BIO-key International, Inc.'s (NASDAQ:BKYI) CEO Pay Packet

First quarter 2021 earnings released: US$0.094 loss per share (vs US$1.84 loss in 1Q 2020)

BIO-key International, Inc Provides Earnings Guidance for the Year 2021

BIO-Key International, Inc. Introduces BIO-key MobileAuth

BIO-key International, Inc. Provides Earnings Guidance for the Fiscal 2021

Full year 2020 earnings released: US$2.08 loss per share (vs US$8.10 loss in FY 2019)

BIO-key International, Inc. to Report Fiscal Year 2020 Results on Mar 25, 2021

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin